|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.
|
12684679 |
2003 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.
|
18095031 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
MDR1 C3435T polymorphism in patients with breast cancer.
|
17560460 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity.
|
26708059 |
2016 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, evaluation of mdr1-RNA seemed to be of little interest in primary breast tumors.
|
8251651 |
1993 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
|
29637742 |
2018 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
|
24886669 |
2014 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies.
|
22311042 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
|
17955490 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, transcripts derived from the MDR1 USP were detected in some drug-resistant cell lines and a high proportion of primary breast tumors (71.6%; n = 61), whereas they were present at low frequency in normal breast tissue (10%; n = 10).
|
15102684 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer.
|
19129072 |
2008 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
|
19001875 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To measure ABCB1 function in tumors, we performed PET experiments using both [<sup>18</sup>F]AVT-011 and [<sup>18</sup>F]FDG in mice bearing orthotopic breast tumors (n = 7-10/group) expressing clinically relevant levels of ABCB1.
|
31729540 |
2019 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this pilot study, MDR1 expression in primary breast tumors was inversely related with the efficacy of first-line chemotherapy, and high expression level was a significant predictor of poor prognosis for patients with advanced disease.
|
12576456 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression level of MDR1 and MRP1 were significantly higher in breast tumors than normal breast tissues.
|
23481629 |
2013 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Reduced ABCB1 protein levels in breast tumors was associated with triple-negative subtype (adjusted odds ratio [OR<sub>adj</sub>] =0.24; 95% confidence interval [CI] =0.13-0.45), lymph node status < pN2 (OR<sub>adj</sub> =0.27; 95% CI =0.10-0.71), tumor size >2 cm (OR<sub>adj</sub> =0.55; 95% CI =0.32-0.93), and hypertensive status (OR<sub>adj</sub> =0.42; 95% CI =0.24-0.73), and it was significantly associated with shorter disease-free survival, either for all breast cancer patients (<i>p</i> log-rank =0.012; hazard ratio [HR] =3.46; 95% CI =1.21-9.91) or for those with triple-negative tumors (<i>p</i> log-rank =0.007; HR =11.41; 95% CI =1.29-100.67).
|
28670140 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
|
16773437 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study, the mechanism of 99mTc-sestamibi uptake by nine human breast tumor cell lines was analyzed as a function of P-glycoprotein (PgP) expression.
|
8667063 |
1996 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Detectable levels of mdr1 mRNA was observed in 25 out of 49 breast tumours, with up to a 100-fold range in expression.
|
1970934 |
1990 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
We determined mRNA levels of BCRP, LRP, MRP1, MRP2, and MDR1 in 59 primary breast tumor specimens of patients who received chemotherapy as first-line systemic treatment after diagnosis of advanced disease.
|
12576456 |
2003 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Taken together, our data indicate that breast tumors with alveolar structures possess resistance to NAC, which is not related to high expression of MDR genes, whereas chemoresistance of tumors with trabecular structures can depend on the expression level of ABCB1.
|
24736530 |
2014 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
|
18654608 |
2009 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
An important result of our study is the demonstration of a correlation between P-gp expression and patients with HER2-positive breast tumors that do not express steroid receptors.
|
29181060 |
2017 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
|
18200595 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1.
|
15498565 |
2004 |